Tara Gangadhar, MD

Tara Gangadhar, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discusses the preference toward front-line single agent immunotherapy in the treatment of melanoma. Gangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.

Videos

Gangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.

Tara Gangadhar, MD | Authors

Articles

Dr. Tara Gangadhar on Single-Agent Versus Dual Immunotherapy Approaches in Melanoma